-
News | 2020.12.01
Embryonic development – the role of Nodal in establishing cardiac asymmetry
Cardiac asymmetry established during embryonic development is critical to heart function. 1% of all newborns are affected by a heart defect, which in France accounts for approximately 8,000 babies per year. It is therefore essential to understand the mechanisms of heart formation in order to determine the causes of these defects. Sigolène Meilhac's Heart Morphogenesis team at the Institut Pasteur...
-
Document de presse | 2022.07.22
Meningref trial shows better protection against meningococcal infection in hematopoietic stem cell transplant recipients
The team in the Hematology Department at Henri Mondor AP-HP Hospital, coordinated by Dr. Christine Robin, and scientists from the Institut Pasteur (the Invasive Bacterial Infections Unit led by Professor Muhamed-Kheir Taha) recently studied protection against meningococcal infection in patients who had received hematopoietic stem cell transplantation.The results of this trial (NCT03509051),...
-
News | 2023.10.02
Malaria: progress towards the use of monoclonal antibodies
Although monoclonal antibodies seem to be a promising avenue for malaria prevention, their mechanism of action remains unclear. Scientists at the Institut Pasteur recently developed a model to study and identify more effective monoclonal antibodies.
-
Document de presse | 2023.10.03
The Institut Pasteur & the University of Tokyo have signed a LOI to establish the Planetary Health Innovation Center, marking the first step towards the Institut Pasteur of Japan
At a ceremony in Tokyo on Tuesday October 3, 2023 attended by the French Ambassador to Japan, H.E. Philippe Setton, the President of the Institut Pasteur, Professor Stewart Cole, and the President and Rector of the University of Tokyo, Professor Teruo Fujii, signed a letter of intent (LOI) to establish the Planetary Health Innovation Center (PHIC), marking the first step towards the Institut...
-
News | 2023.09.29
Foodborne botulism: report on the recent outbreak
In early September 2023, several people were infected after eating home-canned sardines in a bar in Bordeaux. By September 14, 2023, the outbreak had led to the death of one person, and 10 others had been admitted to hospital. Here is a detailed timeline of events and the Institut Pasteur's role in managing this health crisis.
-
News | 2023.04.25
Malaria: improving blood filtration by the spleen to stop the disease transmission
Malaria is a disease transmitted to humans by a mosquito bite, itself infected with a parasite. This parasite settles in the liver, then infects the red blood cells and destroys them. A Université Paris Cité - Inserm team, led by Prof. Pierre Buffet, Medical Vice-President of the Institut Pasteur, identifies two drugs likely to increase the efficiency of blood filtration by the spleen. This can...
-
News | 2025.02.10
The Institut Pasteur and AlterDiag announce the signature of a strategic partnership on research and development of next generation rapid diagnostic technologies
Through this long-term strategic partnership agreement, the Institut Pasteur and AlterDiag will carry out research and development projects to develop new single-domain antibodies (VHH) -based rapid diagnostic tests using lateral flow immunochromatography, with the aim of strengthening the fight against infectious diseases. Scientific and technological collaboration to meet global health...
-
News | 2025.05.30
Institut Pasteur deploys MinoSuiteTM “Pioneer” platform from startup Minos Biosciences, developing next-generation cell analysis technology
With the deployment of its MinoSuiteTM Pioneer platform at the Institut Pasteur, within the Dynamics of Host-Pathogen Interactions unit, headed by Dr. Jost Enninga, deep-tech startup Minos Biosciences has officially launched its Early Access Program. The strategic collaboration between Minos Biosciences and the teams of Jost ENNINGA and Milena HASAN from the Institut Pasteur, partially funded by...
-
Document de presse | 2020.07.15
Type 1 Interferon deficiency: A blood based Signature for Detecting Patients at risk of severe Covid-19 for a therapeutic approach
Which patients will develop a severe form of Covid-19? This is a key question that needs to be answered to improve the individual management and prognosis of patients. In a study published in Science on July 13, teams from AP-HP, Inserm, Université of Paris, Institut Pasteur and Institut Imagine describe a unique and unexpected immunological phenotype in severe and critical patients, consisting...
-
Article | 2019.08.06
Vaccinology and Immunotherapy Initiative: Innovation – Vaccine Candidates
The Institut Pasteur has a distinguished history of vaccine development as a means to improve global health. A stronghold of the Institut Pasteur in vaccines is the development of novel technologies for vaccine design and delivery with several candidates currently under clinical evaluation, either licensed to development and commercialization partners or under Institut Pasteur sponsorship.